A Phase 3 Study Assessing the Addition of High-Dose, Targeted Radiation to the Usual Treatment for Inoperable Non-Small Cell Lung Cancer


Full Title

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (NRG LU008) (CIRB)


Researchers want to see if giving additional radiation therapy to standard treatment helps people with lung cancer to live longer. The people in this study have non-small cell lung cancer (NSCLC) that cannot be removed with surgery (inoperable cancer). The standard treatment includes image-guided radiation therapy (IGRT), chemotherapy, and immunotherapy with durvalumab. 

IGRT uses a computer to make a picture of the tumor and more accurately guide radiation beams (invisible energy waves). The chemotherapy in this study includes 5 anti-cancer drugs. Durvalumab immunotherapy boosts the power of the immune system to fight cancer. These medications are given intravenously (by vein).

The additional radiation therapy to be assessed is called stereotactic body radiation therapy (SBRT). SBRT uses special equipment to deliver radiation to tumors with very high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. If you join this study, you will be randomly assigned to receive the standard NSCLC treatment with or without SBRT.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have inoperable stage 2 or 3 NSCLC.
  • Not have had prior radiation therapy to the area that will be treated with radiation therapy in this study. Up to 4 previous cycles of chemotherapy are allowed.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Jacob Shin’s office at 848-225-6436




Phase III (phase 3)


ClinicalTrials.gov ID